Besides the CDKs targeted by dinaciclib (CDK1, 2, 5, 9), AT7519M also inhibits CDK4, still inducing apoptosis in vitro and in vivo and reducing proliferation in myeloma and CLL [103,104]. Here, CDK1 is linked to plasma cell myeloma.